Will Sanofi, Genzyme chiefs talk deal at JPMorgan?

Could it be time to talk in the long-running saga of Sanofi-Aventis' ($SNY) $18.5 billion bid for Genzyme ($GENZ)? CEOs Chris Viehbacher (photo) and Henri Termeer (photo) will have the chance when they give back-to-back presentation's at next week's JPMorgan Healthcare Conference. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.